Alemtuzumab induces changes in the innate immune system in patients with relapsing-remitting multiple sclerosis

被引：0
|
作者：
Ladwig, A. [1 ]
Suh, J. [1 ]
Schweitzer, F. [1 ]
Roeth, P. [1 ]
Remke, G. [1 ]
Warnke, C. [1 ]
Schroeter, M. [1 ]
Izquierdo-Alvarez, E. [1 ]
Bonmann, E. [2 ]
Fink, G. R. [1 ]
Pallasch, C. [1 ]
Lehmann, H. [1 ]
机构：
[1] Univ Hosp Cologne, Cologne, Germany
[2] Merheim Hosp, Cologne, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0287
引用
收藏
页码：259 / 259
页数：1
相关论文
共 50 条
  • [41] Sustained Positive Effects of Alemtuzumab on Diverse Neurological Functions in Relapsing-Remitting Multiple Sclerosis Patients
    Fox, Edward
    NEUROLOGY, 2010, 74 (09) : A417 - A418
  • [42] Treatment with alemtuzumab after fingolimod in relapsing-remitting multiple sclerosis is effective and safe
    Alcala, C.
    Gascon, F.
    Perez-Miralles, F.
    Dominguez, J. A.
    Garcia Gil-Perotin, S.
    Casanova, B.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 274 - 274
  • [43] Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis
    Zhang, Jian
    Shi, Shengliang
    Zhang, Yueling
    Luo, Jiefeng
    Xiao, Yousheng
    Meng, Lian
    Yang, Xiaobo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (11):
  • [44] Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis
    Rosario Blasco, Maria
    Ramos, Antonio
    Garcia Malo, Celia
    Garcia-Merino, Antonio
    JOURNAL OF NEUROLOGY, 2017, 264 (01) : 168 - 169
  • [45] Cerebral toxoplasmosis in patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab
    Raquel, Calle-Calle
    Lucia, Triguero-Cueva
    Carmen, Valderrama-Martin
    Ana, Romero-Villarrubia
    Antonio, Tapia-Gomez
    Juan, Pasquau-Liano
    Carmen, Arnal-Garcia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39
  • [46] Alemtuzumab/fingolimodSevere activation of relapsing-remitting multiple sclerosis: 3 case reports
    Reactions Weekly, 2018, 1714 (1) : 25 - 25
  • [47] Immunogenicity of alemtuzumab treatment for relapsing-remitting multiple sclerosis: no effect on efficacy or safety
    Selmaj, K.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S247 - S247
  • [48] micro-RNA expression profile in PBMCs changes after alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis
    Ladwig, A.
    Schweitzer, F.
    Klein, I.
    Svacina, M. K. R.
    Wustenberg, H.
    Warnke, C.
    Schroeter, M.
    Bonmann, E.
    Fink, G. R.
    Lehmann, H. C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 665 - 666
  • [49] Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis
    Urshansky, Nataly
    Mausner-Fainberg, Karin
    Auriel, Eitan
    Regev, Keren
    Bornstein, Natan M.
    Karni, Arnon
    JOURNAL OF NEUROIMMUNOLOGY, 2011, 232 (1-2) : 171 - 178
  • [50] Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis
    Yahiya Y. Syed
    Drugs, 2021, 81 : 157 - 168
12345